by telrheum | Jun 19, 2024 | Juvenile Idiopathic Arthritis, Rheumatic Drugs, tumour necrosis factor inhibitors (TNFis)
Background: Juvenile idiopathic arthritis (JIA) is a condition in children causing joint inflammation. Etanercept is a common medication for JIA, but the best dose for effectiveness is unclear. This study looks at whether increasing the dose of etanercept helps...
by telrheum | May 25, 2024 | Biologic Therapy, Colitis, IL-23 Inhibitors, Interleukin Inhibitors, tumour necrosis factor inhibitors (TNFis)
Background Ulcerative colitis is a chronic inflammatory condition affecting the colon. A recent study investigated the effectiveness of combining two drugs, Simponi, which blocks tumor necrosis factor-alpha, and Tremfya, which inhibits interleukin-23. This combination...
by telrheum | Apr 6, 2024 | Biologic Therapy, Rheumatoid Arthritis, tumour necrosis factor inhibitors (TNFis)
This study, conducted by researchers from Yonsei University College of Medicine in South Korea, investigated the risk of cardiovascular events like heart attacks or strokes in patients with ankylosing spondylitis (AS), a type of arthritis affecting the spine. They...
